Compare · AKCA vs AXGT
AKCA vs AXGT
Side-by-side comparison of Akcea Therapeutics, Inc. (AKCA) and Axovant Gene Therapies Ltd. (AXGT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AKCA and AXGT operate in Major Pharmaceuticals (Health Care), so they compete in similar markets.
- Company
- Akcea Therapeutics, Inc.
- Axovant Gene Therapies Ltd.
- Price
- -
- -
- Market cap
- -
- -
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Major Pharmaceuticals
- Major Pharmaceuticals
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- n/a
- News (4w)
- 0
- 0
- Recent ratings
- 0
- 0
Latest AKCA
- Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors
- IMPORTANT SHAREHOLDER ALERT: Halper Sadeh LLP Reminds Shareholders About Its Ongoing Investigations; Investors are Encouraged to Contact the Firm - AKCA, BLDR, DCOM, STND
- SHAREHOLDER ALERT: WeissLaw LLP Reminds AKCA, IMMU, and MXIM Shareholders About Its Ongoing Investigations
- Lifshitz Law Firm, P.C. Announces Investigation of Akcea Therapeutics, Inc. (NASDAQ: AKCA), BMC Stock Holdings, Inc. (NASDAQ: BMCH), Builders FirstSource, Inc. (NASDAQ: BLDR), Cancer Genetics, Inc. (NASDAQ: CGIX), Cellular Biomedicine Group, Inc. (NASDAQ: CBMG), Otelco Inc. (NASDAQ: OTEL), Rosetta Stone Inc. (NYSE: RST), Varian Medical Systems, Inc. (NYSE: VAR), and Yintech Investment Holdings Limited (NASDAQ: YIN)
- Moore Kuehn Encourages RST, AKCA, DCOM, and SBPH Investors to Contact Law Firm
- WAYLIVRA▼® (volanesorsen), the First and Only Therapy for FCS, an Ultra-Rare and Life-Threatening Condition, to Be Available on the NHS in England
- Lifshitz Law Firm, P.C. Announces Investigation of Aimmune Therapeutics, Inc., (NASDAQ:AIMT), Akcea Therapeutics, Inc., (NASDAQ:AKCA), BMC Stock Holdings, Inc., (NASDAQ:BMCH), and Cancer Genetics, Inc., (NASDAQ:CGIX)
- INVESTIGATION ALERT: Halper Sadeh LLP Is Investigating the Following Mergers; Shareholders are Encouraged to Contact the Firm – RST, CBMG, AIMT, AKCA
Latest AXGT
- Axovant Gene Therapies Announces Name Change to Sio Gene Therapies
- Axovant Gene Therapies Announces FDA Clearance of IND for AXO-AAV-GM2 Gene Therapy in Tay-Sachs and Sandhoff Diseases
- Axovant Gene Therapies to Present AXO-Lenti-PD Program Update During Virtual Parkinson’s Disease R&D Day on October 30, 2020
- Why Gastrointestinal (GI) Cancer Drugs Are Expected to See Significant Growth Over Next Few Years
- Axovant Gene Therapies to Host Virtual Parkinson’s Disease R&D Day on October 30, 2020
- Axovant Gene Therapies Receives Rare Pediatric Disease Designation for AXO-AAV-GM1 for GM1 Gangliosidosis
- Axovant Gene Therapies Strengthens Board of Directors and Announces New Chief Commercial Officer
- Axovant Announces Positive Six-Month Follow-Up Data From Second Cohort of SUNRISE-PD Phase 2 Trial of AXO-Lenti-PD Gene Therapy
- Axovant to Participate in Upcoming October Conferences and Provide AXO-Lenti-PD Program Update the Morning of October 6th